Zealand Pharma's Zeydovio Receives Positive EU Panel Recommendation

Key Facts

1Zealand Pharma received a positive opinion from the EU's Committee for Medicinal Products for Human Use (CHMP) for its drug Zeydovio.

2The new drug is intended for the treatment of short bowel syndrome (SBS) in patients.

In a move reflecting ongoing progress within the European biotech sector, Zealand Pharma has received a positive opinion from the EU's Committee for Medicinal Products for Human Use (CHMP) for its drug Zeydovio. The new treatment is specifically intended for patients suffering from short bowel syndrome (SBS). This recommendation serves as a critical regulatory milestone that typically precedes final marketing authorization by the European Commission.

According to reports, this decision represents a major de-risking event for the company, significantly increasing the probability of commercialization within the EU market. This development comes as broader markets digest mixed economic signals, such as the Michigan Consumer Sentiment index which fell to 47.8 on September 11, 2026, per market data.

Looking ahead, investors will monitor the European Commission's timeline for the final approval decision. While the upcoming economic calendar lacks direct pharmaceutical catalysts, market participants are focused on broader sentiment drivers, including a speech by ECB President Christine Lagarde scheduled for later today, September 18, 2026.